REG-4basebio Plc: DNA manufacturing update

4BasebioAnnouncement

15/02/2022 07:15

15 February 2022

4basebio PLC

("4basebio", the "Company" or the “Group”)

DNA manufacturing update

4basebio PLC (AIM: 4BB), the specialist life sciences group focused on
exploiting intellectual property in the field of cell and gene therapies and
DNA and mRNA vaccines, is pleased to provide a trading update in relation to
its synthetic DNA business.

4basebio welcomed Mark Cooper as Head of Manufacturing in December 2021
alongside further senior hires across its manufacturing, quality assurance and
business development teams over recent months.  Mark joins from Abcam plc and
he has assumed responsibility for the Group’s manufacturing facility. 

Despite supply chain and Covid related challenges during construction, the
development of phase one comprising four synthesis rooms is now complete.
Phase two comprising three further synthesis rooms is expected to be completed
in March 2022 and the overall development will be completed within budget.

As reported previously, the facility will be undergoing testing and validation
during Q2 2022. The Company then plans to manufacture and sell research and
pre-clinical grade DNA while working towards securing GMP approvals.

4basebio is also pleased to confirm that the facility handover coincides with
the Company’s first commercial order for research-grade DNA.

Dr Heikki Lanckriet, CEO and CSO for 4basebio, commented: “The combination
of the handover of the clean rooms, recruitment of the manufacturing and
quality assurance teams and the first commercial sale of product all represent
important milestones for 4basebio and its key strategic objective of
commercialising its synthetic DNA technology.”

“4basebio has made significant progress over the past year, with this update
coming a little over a year since the spin out from its former parent
company.  The prospects both for the Group’s DNA technology as well as its
non-viral delivery technology remain very exciting.”

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018).

For further enquiries, please contact:

 4basebio PLC                                                  +44 (0)12 2396 7943 
 Heikki Lanckriet, CEO                                                             
                                                                                   
 Cairn Financial Advisers LLP (Nominated Adviser)              +44 (0)20 7213 0880 
 Jo Turner / Sandy Jamieson                                                        
                                                                                   
 finnCap Ltd (Broker)                                                              
 Geoff Nash/Richard Chambers/Charlotte Sutcliffe/Nigel Birks   +44 (0)20 7220 0500 

Notes to Editors

4basebio (AIM: 4BB) is a specialist life sciences group focused on therapeutic
DNA for cell and gene therapies and DNA vaccines and providing solutions for
effective and safe delivery of these DNA based products to patients. It is the
intention of the Company to become a market leader in the manufacture and
supply of high purity, synthetic DNA for research, therapeutic and
pharmacological use and develop non-viral vectors for the efficient delivery
of payloads. The immediate objectives of 4bb are to validate and scale its DNA
synthesis and advance its collaborations to facilitate the functional
validation of its DNA based products and cell and gene delivery solutions.

Forward-looking statements

This announcement may contain certain statements about the future outlook for
the 4basebio.  Although the directors believe their expectations are based on
reasonable assumptions, any statements about future outlook may be influenced
by factors that could cause actual outcomes and results to be materially
different.



Copyright (c) 2022 PR Newswire Association,LLC. All Rights Reserved